Table 6.
Baseline characteristics and VAP episode description in the statin previous users according to the 30-day mortality
|
Survivors |
Nonsurvivors |
P | |
|---|---|---|---|
| (n = 60) | (n = 33) | ||
| Age (years) |
62.5 (27.0-81.0) |
74.0 (50.0-90.0) |
<0.01 |
| SAPS II (points) |
48.0 (18.0-109.0) |
57.0 (30.0-86.0) |
0.01 |
| Gender, male (n (%)) |
50 (83.3) |
30 (90.9) |
0.31 |
| Hospitalization prior to ICU admission (n (%)) |
41 (68.3) |
23 (69.7) |
0.89 |
| Underlying disease(s) (n (%)) |
|
|
|
| Chronic renal failure |
5 (8.5) |
5 (15.1) |
0.32 |
| Cardiac chronic disease |
38 (64.4) |
27 (81.8) |
0.08 |
| Diabetes mellitus |
19 (32.2) |
10 (30.3) |
0.99 |
| COPD |
15 (25.0) |
9 (27.3) |
0.81 |
| Cirrhosis |
1 (1.7) |
1 (3.3) |
0.67 |
| Immunosuppression |
4 (6.8) |
0 (0.0) |
0.13 |
| Cancer |
7 (11.9) |
3 (9.1) |
0.68 |
| Nursing-home resident (n (%)) |
2 (3.3) |
0 (0.0) |
0.29 |
| Main admission diagnosis |
|
|
|
| Respiratory distress (n (%)) |
21 (35.0) |
12 (36.3) |
0.89 |
| Extrapulmonary sepsis (n (%)) |
19 (31.7) |
14 (42.4) |
0.30 |
| Neurologic failure (n (%)) |
6 (10.0) |
4 (12.1) |
0.75 |
| Abdominal surgery (n (%)) |
2 (3.3) |
0 (0.0) |
0.29 |
| Miscellaneous (n (%)) |
12 (20.0) |
3 (9.1) |
0.17 |
| Nasogastric tube (Yes (%)) |
58 (96.7) |
33 (100) |
0.30 |
| CPIS day-1 |
5.0 (2.0-9.0) |
5.0 (3.0-8.0) |
0.38 |
| CPIS day-3 |
7.0 (5.0-11.0) |
7.0 (5.0-10.0) |
0.30 |
| SOFA day-1 |
7.0 (4.0-15.0) |
10.0 (5.0-16.0) |
<0.01 |
| SOFA day-3 |
7.0 (4.0-14.0) |
8.0 (4.0-15.0) |
0.08 |
| Renal failure on admission (Yes (%)) |
30 (50.0) |
20 (60.6) |
0.33 |
| Serum creatinine (VAP day-1) |
90.0 (27.0-404.0) |
137.0 (34.0-321.0) |
0.02 |
| Serum creatinine (VAP day-3) |
84.0 (14.0-332.0) |
111.0 (27.0-329.0) |
0.20 |
| Length of ICU stay until VAP (days) |
10.0 (2.0-60.0) |
10.0 (2.0-72.0) |
0.90 |
| Duration of MV until VAP (days) |
12.0 (2.0-52.0) |
7.0 (2.0-69.0) |
0.44 |
| Septic shock (VAP day-1) (n (%)) |
18 (30.5) |
17 (51.5) |
0.05 |
| Late-onset VAP (≥5 days after MV onset) (n (%)) |
41 (68.3) |
25 (75.8) |
0.45 |
| MDR bacteria (n (%)) |
19 (32.2) |
14 (42.4) |
0.33 |
| Appropriate antibiotic therapy within the first 24-hour of VAP (n (%)) |
49 (83.0) |
21 (65.6) |
0.06 |
| Steroids therapy during VAP period (n (%)) |
23 (39.6) |
18 (54.5) |
0.17 |
| Statin continuation after ICU admission (n (%)) | 37 (61.7) | 15 (45.4) | 0.13 |
VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CPIS, clinical pulmonary infection score; SOFA, sequential organ failure assessment; MV, mechanical ventilation; MDR, multidrug resistant.